DRUGpreclinicalgene therapy
voyage aav gene therapy
Mechanism
AAV gene therapy delivering codon-optimized SMN1 cDNA. Uses Voyager TRACER platform (target-specific in vivo capsid evolution) for enhanced CNS/spinal-cord tropism vs first-gen AAV9. Novartis license 2022.
Related claims (0)
No claims matched “voyage aav gene therapy” in free-text search.
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.